Drug Trial Radar · NCT00481169
Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Aug 21, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,742
Actual
Start
Jul 2001
Primary completion
Jul 2004
Study completion Sep 2004
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- Female only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether TSE-424 (bazedoxifene acetate), an investigational drug, is safe and effective in the prevention of osteoporosis in postmenopausal women.
Conditions
- Osteoporosis
Interventions
Bazedoxifene Acetate (TSE-424)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percent change from baseline in lumbar spine bone mineral density (BMD) after 24 months.Time frame: 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.